Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial
DOI: 10.1016/j.jtho.2025.12.080
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S1556086425030217
其他信息:
出版社: Elsevier BV
作者: David Planchard; Hye Ryun Kim; Thatthan Suksombooncharoen; Rubi Li; Diego Cortinovis; Ji-Youn Han; Jens Samol; Yotsawaj Runglodvatana; Kang-Yun Lee; Gee-Chen Chang; Chun-Hui Lee; Dariusz Kowalski; Stephanie P.L. Saw; Yiqing Huang; Gerrina Ruiter; Myung-Ju Ahn; Tsung-Ying Yang; Cheng-Ta Yang; Aumkhae Sookprasert; Erica C. Nakajima; Jose Alfon; Robert McEwen; Yi-Ting Chang; James CH. Yang

